- Home
- / Amarin
Amarin
Stock Price
$1.5
2023-03-22
Market Capitalization
$617.9 M
2023-03-22
Revenue
$369.2 M
FY, 2022
Amarin Summary
Company summary
- Overview
- Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases. It develops VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
- Type
- Public
- Status
- Active
- Founded
- 1991
- HQ
- Dublin, IE | view all locations
- Website
- https://amarincorp.com/
- Cybersecurity rating
- ESG rating
Key people
Jan van Heek, Non-Executive Director
Patrick J. O'Sullivan, Non-Executive Director
Kristine Peterson, Non-Executive Director
Operating MetricsView all
Patents (US)
110
19.6%
FY, 2020
Patent Applications (US)
30
FY, 2020
LocationsView all
3 locations detected
Dublin, D HQ
Ireland
Block C, 77 Sir John Rogerson's Quay
Bridgewater Township, NJ
United States
440 Route 22
Zug, ZG
Switzerland
Grafenauweg 8
Amarin Financials
Summary financials
- Revenue (FY, 2022)
- $369.2M
- Gross profit (FY, 2022)
- $243.5M
- Net income (FY, 2022)
- ($105.8M)
- Cash (FY, 2022)
- $217.7M
- EBIT (FY, 2022)
- ($105.9M)
- Enterprise value
- $410.2M
News
Blogs
Footer menu
Products
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension